Related Experiment Videos

"First do no harm" also applies to cancer susceptibility testing

W Burke¹, M J Kahn, J E Garber

¹Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA.

The Cancer Journal From Scientific American

|October 1, 1996

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Genome Wide Conditional Mouse Knockout Resources.

Drug discovery today. Disease models·2024

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.

Breast (Edinburgh, Scotland)·2022

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

See all related articles